Business Description
Silexion Therapeutics Corp is an Israeli biotech firm focused on fighting cancers caused by a gene mutation known as KRAS. The company uses a technique called RNA interference to block the faulty gene signals that drive tumor growth. Its lead treatment, SIL204, is currently being tested in a late-stage clinical trial for pancreatic cancer. Silexion was established in 2008 and operates out of Ramat Gan, Israel.
